Compare · head to head
Novartis vs Roche
Roche ranks higher overall — 360 rank 84 vs 38.
Roche leads on Quality (72 vs 65), Growth (50 vs 37), Safety (68 vs 44) and Sentiment (44 vs 39). The two are close on Value.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | Switzerland | Switzerland |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | XX-Large | XX-Large |
| ISIN | CH0012005267 | CH0012032048 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 38 | 84 |
| Value | 51 | 53 |
| Quality | 65 | 72 |
| Growth | 37 | 50 |
| Safety | 44 | 68 |
| Sentiment | 39 | 44 |
| Quality details | ||
| Profitability | 76 | 87 |
| Cash Truth | 55 | 57 |
Novartis vs AstraZenecaNovartis vs DottikonNovartis vs Sol-Gel TechnologiesNovartis vs BayerAdd a third stock →
Full analyses: Novartis · Roche
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100